# A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

> **NCT02066428** · PHASE1 · COMPLETED · sponsor: **Aeras** · enrollment: 64 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** AERAS-404
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02066428
- **Lead sponsor:** Aeras
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02066428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02066428, "A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02066428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*